CTOs on the Move

Accumulus

www.accumulus.org

 
Accumulus Synergy is a global, non-profit organization that is developing a transformative data exchange platform that aims to enable enhanced collaboration and efficiency between life sciences organizations and global health authorities, while also affording users the ability to extract dynamic, data-driven insights from knowledge management. Sponsored by leading biopharmaceutical companies, Accumulus Synergy was formed in 2020 to create innovative solutions that can reduce regulatory review times and transform global data exchange. The non-profit company is creating a first-of-its-kind cloud-based platform between the biopharmaceutical industry and health authorities worldwide. The single-platform approach aims to improve speed, transparencies and efficiencies in the ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Bill Gibson
Chief Technology Officer Profile
Christopher Jeschke
Chief Technology Officer Profile
Marvin Larry
Chief Information Security Officer Profile

Similar Companies

Impel Pharmaceuticals

Impel Pharmaceuticals specializes in Precision Olfactory Delivery (POD) nasal devices for Alzheimers, migraine, and other central nervous system diseases.

CareFirst Urgent Care

Quality medical attention and care when you need it. All locations offer PCR, Rapid, Antinbody, and Rapid Antibody testing. Open 8am to 8pm, 7 days a week!

Unum Therapeutics

Unum is a Cambridge, MA-based cellular therapeutics company ushering in a new wave of innovation in cancer immunotherapy. Unum has built an antibody-coupled T-cell receptor (ACTR) platform that, when combined with tumor-specific antibodies, directs an individual’s cytotoxic T-lymphocytes (CTLs) to kill tumor cells. In contrast to other approaches that hit a single target and treat a narrow set of tumors, Unum’s approach is not restricted by antigens and may have applications for treating many types of cancers.   Our lead program based on ACTR technology is expected to enter Phase I clinical testing soon to assess safety and efficacy in certain forms of leukemia and lymphoma. In parallel, we are actively seeking partners interested in using the ACTR technology to arm novel proprietary antibodies with a T-cell to improve their therapeutic potential. Working initially to pre-clinically validate antibody-ACTR combinations with partners, we expect to rapidly advance multiple proprietary combinations into clinical testing within the next few years.

Become io

io is a biotechnology company that focuses on improving the quality of protein and overall nutrition through advanced Ingredient Optimized technology. They improve powders and supplements used in food production, transforming the performance of protein...

RHEI Pharmaceuticals

RHEI Pharmaceuticals is a Plainsboro, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.